Meds & supplements › Lonafarnib
Medicine · Farnesyltransferase Inhibitor
ZOKINVY is indicated in patients 12 months of age and older with a body surface area (BSA) of 0.39 m 2 and above: To reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS) For the treatment of processing-deficient…
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
ZOKINVY is indicated in patients 12 months of age and older with a body surface area (BSA) of 0.39 m 2 and above:
ZOKINVY is contraindicated in patients taking:
sofidex [Internet]. Daloreum; c2026. Lonafarnib; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/lonafarnib
sofidex. (2026, August 3). Lonafarnib. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/lonafarnib
Lonafarnib. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/lonafarnib
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.